This brand name is authorized in Nigeria
The drug FEBO-G contains one active pharmaceutical ingredient (API):
|
1
Febuxostat
UNII 101V0R1N2E - FEBUXOSTAT
|
|
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M04AA03 | Febuxostat | M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NG | Registered Drug Product Database | Identifier(s): B4-2598, B4-2599 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
